Efficacy and safety of Jia Wei Bushen Yiqi formulas as an adjunct therapy to systemic glucocorticoids on acute exacerbation of COPD: study protocol for a randomized, double-blinded, multi-center, placebo-controlled clinical trial.
Acute exacerbation of COPD
Design and method
Randomized clinical trial
Systemic glucocorticoids duration
Traditional Chinese medicine
Journal
Trials
ISSN: 1745-6215
Titre abrégé: Trials
Pays: England
ID NLM: 101263253
Informations de publication
Date de publication:
03 Sep 2020
03 Sep 2020
Historique:
received:
23
01
2020
accepted:
11
08
2020
entrez:
5
9
2020
pubmed:
5
9
2020
medline:
22
6
2021
Statut:
epublish
Résumé
Systemic glucocorticoids are effective for the management of chronic obstructive pulmonary disease (COPD) exacerbation but have serious adverse effects. Traditional Chinese medicine (TCM) can bring additional benefits to these patients but has few adverse effects. The present study aims to evaluate the efficacy and safety of Jia Wei Bushen Yiqi (JWBY) formulas in patients who suffer from COPD exacerbations and to investigate whether the short-term (5-days) systemic glucocorticoid therapy is non-inferior to the long-term (9-day) regime. In this multi-center, randomized, double-blinded trial, eligible inpatients with COPD exacerbation are randomly assigned to four groups (A, B, C, and D). Group A will receive placebo plus 5-day prednisone, group B will receive placebo plus 9-day prednisone, group C will receive JWBY formulas plus 5-day prednisone, and group D will receive JWBY formulas plus 9-day prednisone. The primary outcomes are the time interval to the patient's next exacerbation during a 180-day following up and the COPD assessment test (CAT) during treatment. Secondary outcomes include lung function, TCM syndrome assessment, laboratory tests, and safety. The changes of the hypothalamic pituitary adrenaline axis (HPA axis) and inflammatory cytokine will be measured as well. By demonstrating the advantages of utilizing TCM and an appropriate duration of systemic glucocorticoids, this effectiveness comparison trial will provide new references to physicians on how to improve the management of COPD exacerbation. The results of HPA axis and inflammation cytokine measurements will shed light on the molecular mechanisms and entail further mechanism studies. www.chictr.org.cn ChiCTR1900023364. Registered on 24 May 2019.
Sections du résumé
BACKGROUND
BACKGROUND
Systemic glucocorticoids are effective for the management of chronic obstructive pulmonary disease (COPD) exacerbation but have serious adverse effects. Traditional Chinese medicine (TCM) can bring additional benefits to these patients but has few adverse effects. The present study aims to evaluate the efficacy and safety of Jia Wei Bushen Yiqi (JWBY) formulas in patients who suffer from COPD exacerbations and to investigate whether the short-term (5-days) systemic glucocorticoid therapy is non-inferior to the long-term (9-day) regime.
METHODS
METHODS
In this multi-center, randomized, double-blinded trial, eligible inpatients with COPD exacerbation are randomly assigned to four groups (A, B, C, and D). Group A will receive placebo plus 5-day prednisone, group B will receive placebo plus 9-day prednisone, group C will receive JWBY formulas plus 5-day prednisone, and group D will receive JWBY formulas plus 9-day prednisone. The primary outcomes are the time interval to the patient's next exacerbation during a 180-day following up and the COPD assessment test (CAT) during treatment. Secondary outcomes include lung function, TCM syndrome assessment, laboratory tests, and safety. The changes of the hypothalamic pituitary adrenaline axis (HPA axis) and inflammatory cytokine will be measured as well.
DISCUSSION
CONCLUSIONS
By demonstrating the advantages of utilizing TCM and an appropriate duration of systemic glucocorticoids, this effectiveness comparison trial will provide new references to physicians on how to improve the management of COPD exacerbation. The results of HPA axis and inflammation cytokine measurements will shed light on the molecular mechanisms and entail further mechanism studies.
TRIAL REGISTRATION
BACKGROUND
www.chictr.org.cn ChiCTR1900023364. Registered on 24 May 2019.
Identifiants
pubmed: 32883322
doi: 10.1186/s13063-020-04669-5
pii: 10.1186/s13063-020-04669-5
pmc: PMC7468179
doi:
Substances chimiques
Glucocorticoids
0
Types de publication
Clinical Trial Protocol
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
760Subventions
Organisme : Three years to accelerate the development of Chinese medicine in Shanghai, China.
ID : ZY (2018-2020)-FWTX-4016
Organisme : China National Funds for Distinguished Young Scientists
ID : 81704154
Références
Lancet. 2007 Sep 1;370(9589):786-96
pubmed: 17765528
N Engl J Med. 2010 Sep 16;363(12):1128-38
pubmed: 20843247
Ann Intensive Care. 2014 Oct 26;4:32
pubmed: 25593748
Tuberc Respir Dis (Seoul). 2018 Oct;81(4):261-273
pubmed: 29926554
Eur Respir J. 2019 May 18;53(5):
pubmed: 30846476
Am J Respir Crit Care Med. 2011 Sep 15;184(6):662-71
pubmed: 21680942
JAMA. 1994 Nov 16;272(19):1497-505
pubmed: 7966841
Lancet Respir Med. 2018 Jun;6(6):421-430
pubmed: 29650407
Lancet. 2007 Sep 1;370(9589):741-50
pubmed: 17765523
Eur Respir J. 2011 Feb;37(2):264-72
pubmed: 21115606
Clin Chest Med. 2014 Mar;35(1):157-63
pubmed: 24507843
Lancet. 2019 Sep 28;394(10204):1145-1158
pubmed: 31248666
Int J Chron Obstruct Pulmon Dis. 2018 Oct 04;13:3107-3114
pubmed: 30323581
Mediators Inflamm. 2014;2014:651890
pubmed: 25165413
Zhongguo Zhong Xi Yi Jie He Za Zhi. 2007 Apr;27(4):364-7
pubmed: 17526182
Am J Respir Crit Care Med. 2012 Jul 1;186(1):48-55
pubmed: 22447964
Arch Intern Med. 2011 Nov 28;171(21):1939-46
pubmed: 22123804
Int J Chron Obstruct Pulmon Dis. 2014 Apr 25;9:381-95
pubmed: 24812503
Ther Adv Respir Dis. 2018 Jan-Dec;12:1753466618769514
pubmed: 29692212
N Engl J Med. 1999 Jun 24;340(25):1941-7
pubmed: 10379017
JAMA. 2013 Jun 5;309(21):2223-31
pubmed: 23695200
Lancet. 2018 Apr 28;391(10131):1706-1717
pubmed: 29650248
Respiration. 2018;96(4):382-398
pubmed: 30138943
Arch Bronconeumol. 2017 Nov;53(11):611-615
pubmed: 28461091
PLoS One. 2014 Aug 13;9(8):e103168
pubmed: 25118962
J Ethnopharmacol. 2012 Jun 1;141(2):584-91
pubmed: 21911051
Evid Based Complement Alternat Med. 2018 Dec 12;2018:8305892
pubmed: 30643538
BMJ. 2013 Jan 08;346:e7586
pubmed: 23303884
Evid Based Complement Alternat Med. 2018 May 13;2018:1281420
pubmed: 29861765
J Altern Complement Med. 2012 Aug;18(8):731-43
pubmed: 22803654
Respirology. 2012 Feb;17(2):379-89
pubmed: 22122202
Ann Intern Med. 2013 Feb 5;158(3):200-7
pubmed: 23295957
Handb Exp Pharmacol. 2017;237:171-196
pubmed: 27864677
Lancet. 1999 Aug 7;354(9177):456-60
pubmed: 10465169
Chest. 2007 Dec;132(6):1741-7
pubmed: 17646228
BMC Complement Altern Med. 2012 Oct 29;12:197
pubmed: 23107470
Lancet Respir Med. 2016 Jun;4(6):428-30
pubmed: 27185522
Eur Respir J. 2014 Mar;43(3):717-24
pubmed: 23794465
Am J Respir Crit Care Med. 1996 Aug;154(2 Pt 1):407-12
pubmed: 8756814
Eur Respir J. 2017 Mar 15;49(3):
pubmed: 28298398